GISSI-3 trial was a controlled, multicenter, randomized, open-label trial of patients (N=19,394) with acute MI who were randomized to treatment with ZESTRIL (2.5 to 5 mg qd, up to 10 mg qd) with or without IV nitroglycerin (5 to 20 mg/min) begun within 24 hours and continued transdermally for 6 weeks at 10 mg qd. The primary end points were mortality at 6 weeks and the combined end point of death and clinical heart failure beyond day 4 of hospital stay or extensive left ventricular damage. "No ZESTRIL" was either transdermal glyceryl trinitrate or no trial therapy.